Risk factors of immune suppression, viral suppression failure and mortality of HIV-Infected children and adolescents

Authors

  • Suthunya Bunjongpak Department of Pediatrics, Nakhonpathom Hospital

Keywords:

HIV-infected children, antiretroviral therapy, immune suppression, viral suppression

Abstract

Background: To achieve ending AIDs beyond 2030 as UNESCO policy, we studied risk factors of pediatric HIV infection morbidity and mortality at Nakhonpathom Hospital, Thailand. We expected that there is useful information for the development of health service
to improve outcome of pediatric HIV infection care.
Objective: To study risk factors of the failure in restoration of immunity, viral suppression and mortality of HIV-infected children and adolescents.
Method: A retrospective cohort study of HIV-infected children and adolescence (0-20 yearsold) during April 2001 - March 2020 (19 years). Demographic, clinical and laboratory data were collected. Risk factors were analyzed by chi-square and multivariate logistic regression with odds ratio at 95% confidence interval and p-value < 0.005 as statistical significance.
Result: Total 150 patients tested for CD4 were included. Females were 58.7%. The baseline age of antiretroviral therapy (ART) at 5 - 15 years old were 65.7%. The majority (92.6%) received non-PI based regimen and 61% continued same regimen. Weight and height 50 percentiles (PT) increased after antiretroviral therapy (ART) from 25.2% and 24.5% to 42.5% and 43.2%, respectively. The CD4 20% increased after ART from 26.5% to 66.7% and 53.8% had viral suppression (VL < 20 copies/cu.mm.). The majority (87.3%) were alive,
mortality rate was 12.7% and rate of loss to follow up was 12%. Statistical significance risk factors of immune suppression (last CD4 < 20%) were last height < 3rd PT odds ratio = 19.8, poor drug adherence odds ratio = 11.7, last weight < 3rd PT odds ratio = 4.2, baseline height < 3rd PT odds ratio = 2.35, last viral load ≥ 20 copies/cu.mm. odds ratio = 2.1 and delayed ART at > 5 - 15 years old odds ratio = 1.6. Statistical significance risk factors of the failure of viral load suppression (last VL ≥ 20 copies/cu.mm.) were mortality odds ratio = 11.4, first line drug resistance odds ratio = 4.98, poor adherence odds ratio = 3.37, delayed ART at > 5 - 15 years old odds ratio = 2.62 last height < 3rd PT and last CD4 < 20%: same odds ratio = 2.11 and baseline weight < 3rd PT odds ratio = 1.6. Statistic significance risk factors of mortality were delayed ART at > 5 - 15 years old odds ratio = 3.1, poor adherence odds ratio was too high to calculation, low last CD4 level (CD4 < 20%) odds ratio was too high to calculation, last VL ≥ 20 copies/cu.mm. odds ratio = 2.43, baseline weight and height < 3rd PT odds ratio = 13.62, 7.34, respectively and last weight and height < 3rd PT odds ratio
= 20.52, 20.23, respectively.
Conclusion: The risk factors of immune suppression, viral suppression failure and mortality in HIV-infected child and adolescents were poor drug adherence, delayed antiretroviral therapy, low precursor CD4 and failure to thrive.

Downloads

Download data is not yet available.

References

แนวทางการตรวจรักษาและป้องกันการติดเชื้อเอชไอวี ประเทศไทยปี 2560 (Thailand National Guidelines On HIV/AIDS Treatment and Prevention 2016). สำนักโรคเอดส์ วัณโรค และโรคติดต่อทางเพศสัมพันธ์ กรมควบคุมโรค. พิมพ์ครั้งที่ 1 กรุงเทพมหานคร: โรงพิมพ์ บริษัท สหมิตรพริ้นติ้งแอนด์พับลิสชิ่ง จำกัด; พ.ศ. 2560.

ศูนย์อำนวยการบริหารจัดการปัญหาเอดส์แห่งชาติ กรมควบคุมโรค กระทรวงสาธารณสุข. มติการประชุมคณะกรรมการแห่งชาติว่าด้วย การป้องกันและแก้ไขปัญหาเอดส์ ปีงบประมาณ พ.ศ. 2555-2556. ใน เพชรศรี ศิรินิรันดร์, ทวีทรัพย์ ศิรประภาศิริ, วาสนา นิ่มวรพันธุ์, บรรณาธิการ. กรุงเทพมหานคร. บริษัท หกหนึ่งเจ็ด จำกัด. 2556: 4-5.

Diener L, Richardson BA, Chambers EP, John-Stewart GC. Growth reconstitution following antiretroviral therapy and nutritional supplementation: Systemic review and meta-analysis AIDS 2015 PMID: 26355573 Free PMC article. Review

Liu E, Pimpin L, Shulkin M, Kranz S, Duggan CP, Mozaftanan D, Fawzi WW. Effect of Zinc Supplementation on Growth Outcomes in Children under 5 yr of age. Nutrients. 2018; 10: 377.

Jesson J, Koumakpai S, Diagne N R, et al. Effect of Age at Antiretroviral therapy Initiation on Catch-up Growth within the First 24 Monthly Among HIV-Infected Children in the JeDEA West African Pediatric Cohort Pediatr Infect Dis J. 2015; 34(7): e 159-68.

Mc Grath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart GC. Younger age at HAART Initiation is associated with more rapid growth reconstitution. AIDS. 2011; 25: 345-55.

วิศัลย์ มูลศาสตร์, นฤภัค บุญฤทธิภัทร์, ศวิตา อิสสะอาด. ปัจจัยที่มีผลต่อภาวะล้มเหลวทางไวรัสขณะได้รับยา Lopinavir/ritonavir ในผู้ป่วยวัยรุ่น ณ สถาบันบำราศนราดูร. วารสารกุมารเวชศาสตร์. 2556; 52: 61-9.

CauldbeckMB, O’Connor C, O’Connor MB, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther. 2009: 28; 6:7.

Polisser J, Ametonou F, Arrive E, et al. Correlates of adherence to antiretroviral therapy in HIV-infected children in Lomé, Togo, West Africa. AIDS Behav. 2009; 13:23-32.

Kawilapat S, Salvadori N, Ngo-Gians-Huong N, Decker L, et al; Incidence and risk factors of loss to follow-up among HIV-Infected Children in an antiretroviral treatment program. PLOS ONE 14(9): e0222082. doi: 10.1371/journal. pone. 0222082

Wanialwa DC, Obimbo EM, Farquhar Carey, et al. Predictors of Mortality in HIV1 Infected Children on Antiretroviral Therapy in Kenya: A Propective. BMC Pediatr. 2010 May 18; 10: 33 doi: 10.1186/1471-2431-10-33.

Koller M, Patelk, Chi BH, et al. Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries. IeDEA, NISDI, PHACS and IMPAACT 21qC studies J Acquir Immune Defic Syndr. 2015; 68:62-72.

Braidy MT, Oleske JM, Williams PL, et al. Declines in MR and Changes in Causes of death in HIV-1-Infected Children during the HAART era. J Acquir Immune Defic Syndr. 2010; 53: 86.

Traisathit P, Delory T, Ngo-Giang-Huong N, Somsamai R, Techakunakorn P, Theansavettrakul S, et al. Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescent on Antiretroviral: A14-year study in Thailand. J Acquir Immune Defic Syndr. 2018; 77: 17-22

Fernandez LS, Nhampossa T, Fuente SL, et al. Pediatric HIV Care Cascade in Southern Mozambique: Missed Opportunities for Early ART and Re-engagement in Care. Pediatr Infect Dis J 2020; 39: 429-434.

Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana VL, Pattern and Predictors of Immunologic Recovery in Human Immunodeficency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor- Based Highly Active Antiretroviral Therapy. Pediatr Infect Dis J. 2009. 28(6): 488-492.

Lewis J, Walker AS, Castro H, Rossi AD, Gibb DM, et al. Age and CD4 Count at Initiation of Antiretroviral therapy in HIVInfected Children: Effects on Long-term T-Cell Reconstitution. Journal of Infectious Diseases. 2012.205: 548-56.

Rinaldi S, Cotugno N, Pallikkuth S, et al. I-106 Early treatment initiation in children with vertical HIV infection influences HIV specific immune responses. JAIDS. 2019;81: 50.

Bartlett AW, Mohamed TJ, Sudjaritruk T. Disease-and Treatment-related Morbidity in Adolescents with Perinatal HIV Infection in

Asia. Pediatr Infect Dis J 2019; 38(3): 287-92.

Cellins IJ, Jourdain G, Hansudewechakul R, et al. Long-Term Survival of HIV-Infected Children Receiving Antiretroviral Therapy in Thailand: A5-Year Observational Cohort Study. Clin Infect Dis 2010; 51: 1449-57.

Benki-Nugent S, Wamalwa D, Langat A, et al. Comparison of development milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study BMC Pediatr 2017;17: 24.

Puthanakit T, Aurpibul L, Louthrenoo O, et al. Poor cognitive functioning of schoolaged children in Thailand with Perinatally acquired HIV infection taking antiretroviral therapy. AIDS Patient Care STDs 2010; 24:141.

Puthanakit T, Ananworanich J, Vonthanak S, et al. Cognitive function and neurodevelopmental outcomes in HIVinfected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental Study. Pediatr Infect Dis J 2013; 32: 501.

Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012; 26: 1685.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. (2012) Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study PLOS Med 9(9): e1001304. doi: 10.1371/ journal.pmed.1001304

Downloads

Published

2021-03-31

How to Cite

Bunjongpak, S. . (2021). Risk factors of immune suppression, viral suppression failure and mortality of HIV-Infected children and adolescents. Thai Journal of Pediatrics, 60(1), 27–37. retrieved from https://he04.tci-thaijo.org/index.php/TJP/article/view/1194

Issue

Section

Original Articles